Key Points
- Masaru Matsuda sold 8,256 shares on May 4 at an average price of $23.31 for about $192,447 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding from vested awards, trimming his position ~6.1% to 126,689 shares; several other insiders also executed similar sales in early May.
- Mixed Q1 results: ZORYVE net product revenue was $105.4M (up 65% YoY) and revenue beat estimates with positive operating cash flow, but GAAP EPS missed materially (loss of $0.09 vs. expected loss of $0.02); analysts retain a "Moderate Buy" consensus with an average $34 target.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 684 shares of the business's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $23.61, for a total value of $16,149.24. Following the transaction, the insider directly owned 120,466 shares in the company, valued at $2,844,202.26. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Patrick Burnett also recently made the following trade(s):
- On Monday, March 2nd, Patrick Burnett sold 6,287 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.18, for a total value of $158,306.66.
Arcutis Biotherapeutics Stock Performance
Arcutis Biotherapeutics stock opened at $24.17 on Thursday. The firm has a 50 day simple moving average of $23.78 and a 200-day simple moving average of $25.78. Arcutis Biotherapeutics, Inc. has a 1-year low of $12.42 and a 1-year high of $31.77. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.17 and a quick ratio of 2.99. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -172.63 and a beta of 1.58.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The firm had revenue of $105.40 million during the quarter, compared to analysts' expectations of $103.68 million. On average, analysts expect that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current year.
Analyst Upgrades and Downgrades
ARQT has been the subject of several analyst reports. Guggenheim increased their price target on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, February 27th. Mizuho cut their price objective on Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 2nd. Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of Arcutis Biotherapeutics in a research report on Thursday. Wall Street Zen downgraded Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 14th. Finally, TD Cowen raised their price objective on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.00.
Read Our Latest Report on Arcutis Biotherapeutics
Key Headlines Impacting Arcutis Biotherapeutics
Here are the key news stories impacting Arcutis Biotherapeutics this week:
- Positive Sentiment: Strong commercial performance and clinical progress: Q1 net product revenue for ZORYVE was $105.4M (up 65% YoY), the company reported positive operating cash flow, submitted an sNDA to expand ZORYVE to infants 3–24 months, completed enrollment in a pediatric MUSE trial, initiated Phase 1a/1b for ARQ‑234, and expanded the salesforce and primary care/pediatrics buildout. These developments support continued top-line growth and pipeline optionality. Read More.
- Positive Sentiment: Analyst stance remains constructive: Brokerages maintain a consensus "Moderate Buy" and a mid‑$30s consensus target, which can buoy investor sentiment as commercial momentum continues. Read More.
- Neutral Sentiment: Mixed Q1 financials: Revenue beat estimates ($105.4M vs. ~$103.7M) but GAAP EPS missed materially (loss of $0.09 vs. expected loss of $0.02). The top-line strength supports commercialization, but the EPS miss highlights continued margin/expense pressure as the company invests in growth. Read More.
- Negative Sentiment: Insider selling: Multiple insiders (including director and executives) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vested awards. While filings state routine/tax reasons, clustered sales can raise short‑term concerns about insider exposure and add selling pressure. Read More.
Institutional Trading of Arcutis Biotherapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. raised its position in Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company's stock valued at $32,000 after purchasing an additional 833 shares during the period. Global Retirement Partners LLC purchased a new stake in Arcutis Biotherapeutics in the fourth quarter valued at approximately $35,000. EverSource Wealth Advisors LLC raised its position in Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company's stock valued at $37,000 after purchasing an additional 698 shares during the period. NewEdge Advisors LLC raised its position in Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company's stock valued at $45,000 after purchasing an additional 1,045 shares during the period. Finally, Johnson Investment Counsel Inc. purchased a new stake in Arcutis Biotherapeutics in the third quarter valued at approximately $30,000.
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
